A triple drug approach that blocks the KRAS pathway at three points eliminated pancreatic tumors and prevented resistance in ...

For the first time in 30 years, there is a new FDA-approved treatment for locally advanced pancreatic cancer.

Clinically available KRAS inhibitors mainly target G12C, which is rare in PDAC and often acquires resistance. Oncogenic KRAS inactivates RB1 via CDK4/6, while RB1 mutation is rare. Thus, CDK4/6 ...

Explore the latest colorectal cancer treatment advances, from precision oncology and immunotherapy to ADCs, bispecifics, and ...

Cancer death rates in the UK have hit a record low, but the picture is more complicated than the headline figure suggests.

Hepatobiliary and pancreatic tumors represent a critical area of oncological research due to their aggressive nature, limited ...

Clinically available KRAS inhibitors mainly target G12C, which is rare in PDAC and often acquires resistance. Oncogenic KRAS inactivates RB1 via CDK4/6, while RB1 mutation is rare. Thus, CDK4/6 ...

Event-driven primary disease-free survival ('DFS”) analysis for Phase 2 AMPLIFY-7P study evaluating ELI-002 7P in patients with pancreatic ductal adenocarcinoma ('PDAC”) is anticipated in 1H 2026Fewer ...

Candel Therapeutics Inc (NASDAQ:CADL) is advancing plans to bring its lead cancer immunotherapy toward potential ...

With the amazing advances in medicine in the last one hundred years, we are living longer and generally enjoying a higher ...

Researchers discovered that exposing cancer cells to vibration mimicking vocal cord movement reduced their malignancy.

Injecting viral peptides systemically into mice activated immune cells that then targeted pancreatic tumors, opening avenues to more accessible cancer therapy.